Press
· News

POELLATH advises the shareholders of KLIFOVET AG on sale to Argenta Limited

POELLATH has advised the shareholders of KLIFOVET AG (“Klifovet”), the leading European Contract Research Organization (CRO) and Regulatory Affairs consultancy organization, on its sale to Argenta Limited (“Argenta”), a global contract research, development and manufacturing organization dedicated to animal health. Klifovet founder and CEO Dr. Klaus Hellmann will continue to lead Klifovet and will join Argenta’s senior leadership team.

Founded in 1997 and based in Munich (Germany), Klifovet AG is a full-service Contract Research and Development Organization (CRO) with extensive expertise in clinical research and regulatory affairs. The company employs approximately 50 people who have successfully participated in several hundred studies and whose expertise and knowledge has been critical to numerous marketing authorizations for pharmaceutical, biological, immunological, and novel therapies. Klifovet's customers include the world’s leading animal health and nutrition companies, as well as many promising start-ups.

Argenta was founded in New Zealand in 2006. The company operates from “molecule to market” in partnership with clients of all sizes from all parts of the world, supporting them in research & development, clinical research, regulatory affairs, scale up and manufacturing needs along their veterinary product development journey. Argenta has research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, making it the only global contract research, development and manufacturing organization dedicated to animal health.

POELLATH provided comprehensive legal advice to the shareholders of Klifovet in connection with the sale with the following team:

Other advisors on the seller side included Kevin Grové of OGIER on legal aspects under Jersey law.

Press contact
Services